Any current/future new fundraising through debt or equity?

There is no specific mention of any current or immediate new fundraising through debt or equity in the call. The company mentioned having a debt of Rs. 759 crores in Q1 FY25, reduced from Rs. 804 crores last quarter (a Rs. 45 crore reduction). They plan to optimize CAPEX and improve debt-equity ratios starting next year, with a focus on continuous debt reduction. Interest costs have increased due to capitalization of assets; these costs are expected to be absorbed over time as production ramps up. CAPEX for the current year is guided to be around Rs. 120 to Rs. 140 crores, mainly for debottlen

Any current/future capex/capital investment/strategic investment?

Current CAPEX guidance for FY25 is approximately Rs. 120 to Rs. 140 crores, primarily focused on debottlenecking and maintenance, with no major significant new CAPEX planned currently. Recent CAPEX of Rs. 600 to Rs. 800 crores has been done over the last three years, achieving 1.3x to 1.5x asset turnover. Capitalization of new assets in the last 12 months has increased depreciation and interest costs, expected to be absorbed as production and sales ramp up. Future CAPEX is planned for expansion in Crop Protection, Animal Health, and Pharma divisions, with validation activities ongoing, a

Future growth expectations in sales/revenue/volumes?

Hikal Limited expects 10%-15% CAGR growth over the next 2-3 years starting next fiscal year, driven by ramp-up in new molecules and normalization in crop protection demand (Page 13). Pharma business anticipates good volume growth due to capacity expansions and robust product pipeline, with 2-3 new product launches annually (Page 5). Crop protection business faces short-term challenges but expects market improvement by Q3/Q4 FY25, supporting mid to long-term growth (Pages 4, 7). CDMO segment is seeing increased customer inquiries and opportunities, with projects expected to reach peak potent

Future growth expectations in earnings/operating earnings/profits/EPS?

Hikal Limited expects 10%-15% revenue CAGR over the next 2-3 years, starting next fiscal year, driven by recovery in crop protection and growth in pharma and animal health divisions. EBITDA margins expected to reach historical levels of 18%-20% post FY26, with peak margin reflection anticipated about 3-5 years from now as new molecules scale up commercially (likely by FY29 or FY30). Growth in pharma CDMO and niche specialty products will drive higher material gross margins, potentially north of 60%, improving blended margins from the current ~45%. Operating leverage is expected with capa

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide explicit details about the current or expected order book or pending orders in quantitative terms. However, it mentions a "growing number of inquiries and conversions to form business" in the CDMO segment, indicating a strong interest and pipeline. The Crop Protection business is actively engaged in several projects with existing and new innovator customers, many in advanced stages of discussion. The Animal Health segment is in the validation phase for several molecules with discussions ongoing for new customers, showing positive signs. Overall, the company show

HikalQ1 FY25Pharmaceuticals & Biotechnology

Hikal Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹218P/E: 63.3Market Cap: ₹2.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Hikal Limited expects 10%-15% CAGR growth over the next 2-3 years starting next fiscal year, driven by ramp-up in new molecules and normalization in crop protection demand (Page 13).
Pharma business anticipates good volume growth due to capacity expansions and robust product pipeline, with 2-3 new product launches annually (Page 5).
Crop protection business faces short-term challenges but expects market improvement by Q3/Q4 FY25, supporting mid to long-term growth (Pages 4, 7).
CDMO segment is seeing increased customer inquiries and opportunities, with projects expected to reach peak potential within 2 years (Pages 9, 10).
Animal health business is in validation phase, expecting revenues to start accruing around 14-16 months post-validation, indicating growth potential over next 5 years (Page 10).
Overall, the company aims to double revenue over 3-4 years from FY23 base of Rs. 2000 crores through diversification and new business streams (Page 11).

Margin guidance

Category 3

Hikal Limited expects 10%-15% revenue CAGR over the next 2-3 years, starting next fiscal year, driven by recovery in crop protection and growth in pharma and animal health divisions.
EBITDA margins expected to reach historical levels of 18%-20% post FY26, with peak margin reflection anticipated about 3-5 years from now as new molecules scale up commercially (likely by FY29 or FY30).
Growth in pharma CDMO and niche specialty products will drive higher material gross margins, potentially north of 60%, improving blended margins from the current ~45%.
Operating leverage is expected with capacity debottlenecking and regulatory approvals, leading to better profitability through FY25 and beyond.
Interest costs currently higher due to asset capitalization but expected to reduce and improve net profits as production ramps up.
Focus remains on profitability and margin quality over aggressive growth; management is cautiously optimistic about sustainable and profitable expansion.

See what Hikal management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any current or immediate new fundraising through debt or equity in the call.
The company mentioned having a debt of Rs. 759 crores in Q1 FY25, reduced from Rs. 804 crores last quarter (a Rs. 45 crore reduction).
They plan to optimize CAPEX and improve debt-equity ratios starting next year, with a focus on continuous debt reduction.
Interest costs have increased due to capitalization of assets; these costs are expected to be absorbed over time as production ramps up.
CAPEX for the current year is guided to be around Rs. 120 to Rs. 140 crores, mainly for debottlenecking and maintenance, with no major significant CAPEX planned.
No explicit plans for raising funds via equity or debt were disclosed during the call.

Order book

Yes

The transcript does not provide explicit details about the current or expected order book or pending orders in quantitative terms.
However, it mentions a "growing number of inquiries and conversions to form business" in the CDMO segment, indicating a strong interest and pipeline.
The Crop Protection business is actively engaged in several projects with existing and new innovator customers, many in advanced stages of discussion.
The Animal Health segment is in the validation phase for several molecules with discussions ongoing for new customers, showing positive signs.
Overall, the company shows a robust product development pipeline with 8-9 products in progress and 2-3 new product launches expected annually.
Despite current industry challenges, there is confidence in improved market demand and expansion in new geographies, suggesting a healthy future order pipeline.

See what Hikal management said on order book — free account, 30 seconds.

Capex plans

Yes

Current CAPEX guidance for FY25 is approximately Rs. 120 to Rs. 140 crores, primarily focused on debottlenecking and maintenance, with no major significant new CAPEX planned currently.
Recent CAPEX of Rs. 600 to Rs. 800 crores has been done over the last three years, achieving 1.3x to 1.5x asset turnover.
Capitalization of new assets in the last 12 months has increased depreciation and interest costs, expected to be absorbed as production and sales ramp up.
Future CAPEX is planned for expansion in Crop Protection, Animal Health, and Pharma divisions, with validation activities ongoing, and regulatory filings expected to significantly contribute to growth.
No specific large-scale strategic investments announced, but focus remains on capacity expansion, cost efficiencies, and operational optimization to support 10-15% growth from FY26 onwards.

Track Hikal — get its next earnings analysis in your feed

How does Hikal rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisHikal

Rev 3Mar 3

See where Hikal sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Hikal rank in Pharmaceuticals & Biotechnology?

Compare Hikal against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Hikal Q1 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Hikal rank in Pharmaceuticals & Biotechnology?

Continue your research

What Hikal's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season